
Despite some ups and downs, Johnson & Johnson's (NYSE:JNJ) pharmaceutical division consistently outperforms its peers in terms of branded drug sales. As a result, pharmaceutical sales are now responsible for a majority of the healthcare conglomerate's total revenue.
Sales of J&J's former top product, Remicade, have started sliding, thanks to competition from lower-cost biosimilars. The company recently presented a smorgasbord of reasons why its pharmaceutical segment can continue outperforming despite the pressure. Here are six of the most important ones J&J wants you to know about.
Image source: Getty Images.
1. Doing better than you might thinkThanks to consumer and medical-device segments that have been taking steps back, overall annual revenue rose from a meager $74.3 billion in 2014 to $81.6 billion in 2018. The company's a long way from a crisis, though, thanks to pharmaceutical sales that have been growing a lot faster than you might think. [Read More]
Published @ May 18, 2019
Related Videos
Johnson & Johnson’s Earnings: What's this Company's Secret?
Johnson & Johnson (NYSE: JNJ) is a healthcare Goliath that generates billions of dollars in revenue from consumer goods, pharmaceuticals, and medical ...

This article has been generated by our Automated Marketing Solution at www.ProsConnected.com. Our system carefully created this article to attract you to read it and then next thing you know, you’re reading what you’re reading now!
The same thing can happen to YOUR Business! It only takes 5 minutes to get setup in the system and then you can just literally PLUG-IN ProsConnected into your website and start receiving organic traffic.

Comments
Post a Comment